Aggressive Lymphomas
News
‘Excellent’ survival with HCT despite early treatment failure in FL
Autologous and allogeneic hematopoietic stem cell transplantation (HCT) both offer excellent long-term survival in follicular lymphoma (FL)...
Conference Coverage
Interim PET scans identify HL patients with better outcomes
CHICAGO—Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after...
From the Journals
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
News
FDA approves pembrolizumab for relapsed/refractory PMBCL
The FDA granted accelerated approval based on results from the KEYNOTE-170 trial.
News
FDA grants pembrolizumab accelerated approval for PMBCL
The US Food and Drug Administration (FDA) granted accelerated approval to the anti-PD-1 therapy pembrolizumab (Keytruda) for the treatment of...
Conference Coverage
Ibrutinib and venetoclax combo promising in frontline CLL
CHICAGO—Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic...
Conference Coverage
Chemo-free combo provides potential first-line option for FL
CHICAGO—A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus...
News
FDA approves venetoclax for CLL/SLL with or without del 17p
The US Food and Drug Administration (FDA) has approved venetoclax tablets (Venclexta ®) in combination with rituximab to treat patients with...
Conference Coverage
Polatuzumab plus BR improves efficacy in DLBCL
CHICAGO—Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of...
Conference Coverage
Chemo-free regimen appears viable in previously untreated FL
CHICAGO – Could lenalidomide plus rituximab be a first-line option?
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.